T‐cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis | Zendy

Dubal Dena B. | Zendy; Mueller Sabine | Zendy; Ruben Beth S. | Zendy; Engstrom John W. | Zendy; Josephson S. Andrew | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

T‐cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis

Author(s) -

Dubal Dena B.,

Mueller Sabine,

Ruben Beth S.,

Engstrom John W.,

Josephson S. Andrew

Publication year - 2009

Publication title -

muscle and nerve

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 145

eISSN - 1097-4598

pISSN - 0148-639X

DOI - 10.1002/mus.21306

Subject(s) - myasthenia gravis , mycophenolate , medicine , prednisone , adverse effect , complication , mycophenolic acid , post transplant lymphoproliferative disorder , lymphoproliferative disorders , dermatology , immunosuppressive drug , immunology , gastroenterology , surgery , transplantation , lymphoma , rituximab

Immunosuppressive therapies are critical in the management of numerous conditions including myasthenia gravis. Mycophenolate mofetil is a widely used, oral immunosuppressive agent that is considered to have few adverse effects compared with similar drugs. We report the case of a patient who developed T‐cell lymphoproliferative lesions following long‐term treatment with mycophenolate mofetil and prednisone for myasthenia gravis. The lesions resolved following cessation of the treatment. This case highlights a serious complication of a commonly used drug. Muscle Nerve, 2009

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research